February 25, 2026

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Conexiant

January 14, 2026

FDA Clears Rayner's Sophi Phaco System

The company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility.

Ophthalmology Management

January 06, 2026

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

Retinal Physician

January 04, 2026

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

Contact Lens Spectrum

January 02, 2026

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

Ophthalmology Management

December 19, 2025

FDA Approves Uplizna for Adults Who Have Generalized Myasthenia Gravis

The approval offers patients a new targeted treatment option that has the potential for long-term disease control with 2 doses a year, after 2 initial loading doses, says Amgen.

Ophthalmology Management

December 18, 2025

FDA Approves Generic Travoprost Option

Alembic gains approval for an ionic-buffered travoprost equivalent to Travatan Z.

Glaucoma Physician

December 02, 2025

FDA Approves Amneal’s Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye

Cyclosporine ophthalmic emulsion 0.05% is the generic equivalent of Restasis, a registered trademark of Allergan, an AbbVie company.

Ophthalmology Management

November 24, 2025

Eylea HD Approved for RVO

The FDA approval allows extended dosing intervals following initial monthly therapy.

Retinal Physician